Literature DB >> 16807780

Medical management of patients with brain tumors.

Patrick Y Wen1, David Schiff, Santosh Kesari, Jan Drappatz, Debra C Gigas, Lisa Doherty.   

Abstract

The most common medical problems in brain tumor patients include the management of seizures, peritumoral edema, medication side effects, venous thromboembolism (VTE), fatigue and cognitive dysfunction. Despite their importance, there are relatively few studies specifically addressing these issues. There is increasing evidence that brain tumor patients who have not had a seizure do not benefit from prophylactic antiepileptic medications. Patients on corticosteroids are at greater risk of Pneumocystis jerovecii pneumonia and may benefit from prophylactic therapy. There is also growing evidence suggesting that anticoagulation may be more effective than inferior vena cava IVC) filtration devices for treating VTE in brain tumor patients and the risk of hemorrhage with anticoagulation is relatively small. Low-molecular weight heparin may be more effective than coumadin. Medications such as modafinil and methylphenidate have assumed an increasing role in the treatment of fatigue, while donepezil and memantine may be helpful with memory loss.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807780     DOI: 10.1007/s11060-006-9193-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  194 in total

1.  Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study.

Authors:  Yuriko Sugawara; Tatsuo Akechi; Yasuo Shima; Toru Okuyama; Nobuya Akizuki; Tomohito Nakano; Yosuke Uchitomi
Journal:  Palliat Med       Date:  2002-05       Impact factor: 4.762

2.  Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy?

Authors:  P M Foy; D W Chadwick; N Rajgopalan; A L Johnson; M D Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

3.  Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

Review 4.  Current treatments of epilepsy.

Authors:  Siddhartha Nadkarni; Josiane LaJoie; Orrin Devinsky
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

5.  Hydrocephalus in radiation leukoencephalopathy: results of ventriculoperitoneal shunting.

Authors:  B Thiessen; L M DeAngelis
Journal:  Arch Neurol       Date:  1998-05

6.  Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.

Authors:  Agnes Y Y Lee; Frederick R Rickles; Jim A Julian; Michael Gent; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Mark N Levine
Journal:  J Clin Oncol       Date:  2005-02-07       Impact factor: 44.544

7.  Corticotropin-releasing factor decreases vasogenic brain edema.

Authors:  J Tjuvajev; H Uehara; R Desai; B Beattie; C Matei; Y Zhou; M J Kreek; J Koutcher; R Blasberg
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

8.  Methylphenidate in terminal depression.

Authors:  A D Macleod
Journal:  J Pain Symptom Manage       Date:  1998-09       Impact factor: 3.612

Review 9.  Decreased phenytoin levels in patients receiving chemotherapy.

Authors:  S A Grossman; V R Sheidler; M R Gilbert
Journal:  Am J Med       Date:  1989-11       Impact factor: 4.965

10.  Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors.

Authors:  Anuj K Mahindra; Stuart A Grossman
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.506

View more
  32 in total

1.  Infections in neuro-oncology.

Authors:  P Gaviani; A Silvani; E Lamperti; A Botturi; G Simonetti; I Milanesi; D Ferrari; A Salmaggi
Journal:  Neurol Sci       Date:  2011-11       Impact factor: 3.307

2.  Lecture: profile of risks and benefits of new antiepileptic drugs in brain tumor-related epilepsy.

Authors:  Marta Maschio; L Dinapoli
Journal:  Neurol Sci       Date:  2011-11       Impact factor: 3.307

Review 3.  Antiangiogenic strategies for treatment of malignant gliomas.

Authors:  Andrew S Chi; Andrew D Norden; Patrick Y Wen
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 4.  Practical management of bevacizumab-related toxicities in glioblastoma.

Authors:  Alba A Brandes; Marco Bartolotti; Alicia Tosoni; Rosalba Poggi; Enrico Franceschi
Journal:  Oncologist       Date:  2015-01-07

5.  Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.

Authors:  Alexander K Berg; Jan C Buckner; Evanthia Galanis; Kurt A Jaeckle; Matthew M Ames; Joel M Reid
Journal:  J Clin Pharmacol       Date:  2015-06-26       Impact factor: 3.126

6.  Retinoic acid as target for local pharmacokinetic interaction with modafinil in neural cells.

Authors:  Julian Hellmann-Regen; Karen Gertz; Ria Uhlemann; Michael Colla; Matthias Endres; Golo Kronenberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-21       Impact factor: 5.270

7.  Incidence of thromboembolic events after use of gelatin-thrombin-based hemostatic matrix during intracranial tumor surgery.

Authors:  Roberto Gazzeri; Marcelo Galarza; Carlo Conti; Costanzo De Bonis
Journal:  Neurosurg Rev       Date:  2017-04-24       Impact factor: 3.042

8.  Epilepsy is related to theta band brain connectivity and network topology in brain tumor patients.

Authors:  Linda Douw; Edwin van Dellen; Marjolein de Groot; Jan J Heimans; Martin Klein; Cornelis J Stam; Jaap C Reijneveld
Journal:  BMC Neurosci       Date:  2010-08-23       Impact factor: 3.288

9.  Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

Authors:  Santosh Kesari; David Schiff; Lisa Doherty; Debra C Gigas; Tracy T Batchelor; Alona Muzikansky; Alison O'Neill; Jan Drappatz; Alice S Chen-Plotkin; Naren Ramakrishna; Stephanie E Weiss; Brenda Levy; Joanna Bradshaw; Jean Kracher; Andrea Laforme; Peter McL Black; Judah Folkman; Mark Kieran; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2007-04-23       Impact factor: 12.300

10.  Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Authors:  D A Reardon; A Desjardins; J J Vredenburgh; S Gururangan; J H Sampson; S Sathornsumetee; R E McLendon; J E Herndon; J E Marcello; J Norfleet; A H Friedman; D D Bigner; H S Friedman
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.